Objective: Venous valves are essential but are prone to injury, thrombosis, and fibrosis. We compared the behavior and gene expression of smooth muscle cells (SMCs) in the valve sinus vs nonvalve sites to elucidate biologic differences associated with vein valves.
saphenous veins are used for arterial bypass, stenotic lesions frequently occur at valve sites. [4] [5] [6] [7] Studies in mice have led to a good understanding of the role of endothelial cells in venous valve development. 8 There is also a reasonable understanding of the venous response to injury from studies of arterialized animal vein grafts and of human veins and venous tissue perfused or cultured ex vivo, [9] [10] [11] but there is essentially nothing known about the response to injury of the animal or human venous valve wall area specifically. Our approach has been to use human venous tissue explants as an ex vivo model of injury. We have previously shown that arterial tissue explants demonstrate many of the same responses observed in the injured artery in vivo. For example, growth factor requirements for cell migration as well as the kinetics of cell migration, proliferation, and production of matrix-degrading proteinases are the same in vivo as in tissue explants. [12] [13] [14] Whereas the rheology and hemodynamics at the valve sinus may underlie some of the problems at valve sites, we hypothesized that there are unique biologic and cellular characteristics of the venous smooth muscle cell (SMC) at valve sites. Using human saphenous veins, we now report an exaggerated response to injury by SMCs of the valve wall as evidenced by increased SMC proliferation and migration compared with nonvalve wall SMCs.
METHODS

Methods are briefly outlined here. Complete methods are available online (Supplementary Methods, online only).
Veins, tissue culture, and cell culture. Human saphenous vein remnants were obtained from patients undergoing coronary artery bypass or peripheral vascular bypass operations. All subjects gave informed consent as approved by the Institutional Review Boards of the University of Washington and the Benaroya Research Institute (the latter for anonymous tissues only, which provided the majority of subjects). After dissection of periadventitial tissue and removal of the endothelium and valve leaflets, segments of valve sinus were separated from remaining segments ( Supplementary Fig 1, online only). The intimal-medial layer containing SMCs was dissected from the adventitia, and uniform explants of both layers were made using a tissue chopper. Migration of cells from tissue explants was assessed daily, as follows: (1) an explant was called migration positive if at least one attached, spread cell was observed outside the explant; and (2) the number of migrated cells (up to 100) was counted for each explant. The first method measures only migration, whereas the second method measures the combination of migration and postmigration proliferation. [13] [14] [15] When needed, various reagents were added with the growth medium, which was changed every 2 days. Cells obtained from explants were passaged and used for subsequent experiments.
Tissue histology and immunostaining. To compare SMC proliferation (Ki67 immunostaining) and death (terminal deoxynucleotidyl transferase dUTP nick end labeling) in valve vs nonvalve wall, veins were cleaned of periadventitial tissue and opened longitudinally. Specimens with contiguous valve and nonvalve areas were cut into 2-mm-wide, full-thickness (ie, with adventitia and intima-media) longitudinal specimens and cultured up to 4 days.
Cell migration, growth, and attachment. Cell migration was performed using both microchemotaxis chambers (Neuro Probe, Inc, Gaithersburg, Md) 16 and scratch migration assays. A 3-day growth assay and the crystal violet assay were used to measure growth and attachment, respectively. 16 RNA sequencing and pathway enrichment analysis. RNA was purified from intima-media specimens from valve and nonvalve areas that were either immediately frozen or cultured for 2 days. Single-read sequencing was carried out to generate approximately 10 million reads per sample. Differentially expressed genes and Gene Ontology (GO) terms that were over-represented or under-represented by the differentially expressed genes in the valve and day comparisons were determined.
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RESULTS
Increased SMC migration and proliferation in tissue explants of the valve sinus wall. SMCs from explants of the intima-media of the valve sinus wall (hereafter just called valve) migrate from explants 1 day sooner than SMCs from nonvalve intima-media. This was true for both the percentage of migration-positive explants (Fig 1, A , left panel) and the number of cells per explant (Fig 1, A , right panel). In contrast, the adventitial tissue explants showed no difference in the rate of migration of cells from valve vs nonvalve areas of the vein (Fig 1, B) .
There were no significant differences between the valve and the nonvalve intima-media or adventitia in terms of cell density (Fig 2, A, left and right panels, respectively) or cell death (terminal deoxynucleotidyl transferase dUTP nick end labeling staining; Fig 2, B, left and right panels, respectively) in response to the injury of tissue dissection. However, SMC proliferation was higher by 4 days in the valve intima-media compared with the nonvalve intima-media (Ki67 staining; Fig 2, C, left panel) . There was no difference in cell proliferation in the valve vs nonvalve adventitia (Fig 2, C, right panel) . Thus, valve SMCs show increased rates of migration from tissue and proliferation in tissue in response to the injury of dissection and culture. Our subsequent studies focused on the intima-media tissue and their SMCs because there was no valve effect on the adventitia.
ARTICLE HIGHLIGHTS
Cultured valve SMCs also migrate and proliferate faster than nonvalve SMCs. To determine if the increased migratory activity of valve SMCs is a stable phenotype, we studied cultured SMCs derived from valve and nonvalve segments, at passage 6. There were no statistically significant differences in the general SMC phenotype of valve vs nonvalve cells, as measured by a wide variety of parameters: expression of smooth muscle a-actin or smooth muscle myosin heavy chain by immunofluorescence (Fig 3, A-C) ; messenger RNA expression of smooth muscle a-actin (ACTA2), smooth muscle myosin heavy chain (MYH11), caldesmon 1 (CALD1), or NG2 (CSPG4 ; Fig 3, D) . We found that valve SMCs migrated w60% faster than nonvalve SMCs in response to both platelet-derived growth factor (PDGF) subunit BB (PDGF-BB) and 10% serum (Fig 4, A) . The increased migration in response to PDGF-BB was due to increased chemotactic activity because the difference between valve SMCs and nonvalve SMCs was not observed when PDGF was placed in both the top and bottom chambers (Fig 4, B) . In contrast, in response to serum, the increased migration by valve SMCs was due to increased chemokinetic activity (Fig 4, C) . This difference was not due to differences in attachment to the polymeric collagen used for the migration assay as attachment was the same for both types of SMCs (Fig 4, D) .
Proliferation of valve SMCs was also greater than that of nonvalve SMCs in response to PDGF-BB (Fig 5, A) . In contrast, proliferation in response to 1% to 10% serum or to a commercial SMC growth medium that contains 5% fetal bovine serum and unknown amounts of fibroblast growth factor 2 (FGF2), epidermal growth factor, insulin, and heparin was no different between valve and nonvalve SMCs (Fig 5, B and C).
FGF2 is required for the increased migration and proliferation of cultured valve SMCs. We previously reported that PDGF-mediated proliferation of human arterial SMCs is partially mediated through the release of Therefore, we hypothesized that PDGF mediates valve SMC migration and proliferation because of increased heparin-sensitive FGF2 in valve SMCs. However, we found no difference in the amount of FGF2 in the heparinreleasable fraction, medium, or cell layer in valve and nonvalve SMCs before or after treatment with PDGF-BB ( Supplementary Fig 2, A, online only). In addition, we found no difference in the relative amounts of the 18-kD, 22-kD, and 28-kD FGF2 isoforms, which can have different activities (Supplementary Fig 2, B, online only). 19 Although FGF2 levels were the same for valve and nonvalve SMCs, we found that blockade of FGF2 with FGF2 antibody inhibited most of the increased migration (Fig 6, A) and proliferation (Fig 6, B) of valve SMCs in response to PDGF-BB and did not change the migration or proliferation of nonvalve SMCs. Finally, valve but not nonvalve SMCs showed increased migration in response to FGF2 (Fig 6, C) , indicating that FGF2 signaling is functional in valve SMCs but not in nonvalve SMCs. In combination, these data suggest that the FGF2 mechanisms mediating migration and proliferation are functional and operative in valve SMCs but not in the nonvalve SMCs. We also observed another valve-specific effect regarding PDGF-BB-mediated migration. Anti-PDGF receptor (PDGFR) b only partially inhibited the PDGF-BB-induced Supplementary Fig 3, A, left panel, online only) but completely blocked nonvalve SMC migration. Using a combination of maximally effective anti-PDGFRa and PDGFRb also did not completely block the effect of PDGF-BB in the valve SMCs ( Supplementary Fig 3, B, online only) , whereas a combination of anti-FGF2 and anti-PDGFRb inhibited PDGF-BB-mediated valve SMC migration >90% (Supplementary Fig 3, C, online only) .
The inability to completely block PDGF-BB-mediated migration in the valve SMCs with the combination of anti-PDGFRa and anti-PDGFRb was surprising because Valve smooth muscle cells (SMCs) show increased chemotactic migration to platelet-derived growth factor subunit BB (PDGF-BB) and increased chemokinetic migration to serum. Valve and nonvalve SMC migration was measured using a microchemotaxis chamber assay. A, Migration in response to PDGF-BB or 10% fetal bovine serum (FBS). *P < .01 valve vs nonvalve; results are from paired cells from seven veins. SFM, Serumfree medium. B and C, Valve and nonvalve SMC migration was determined in microchemotaxis chambers with either 10 ng/mL PDGF-BB (B) or 10% serum (C) in only the bottom chamber or in both top and bottom chambers. *P < .01 top only vs top and bottom; n ¼ 5 experiments. D, Attachment of SMCs to polymeric collagen measured using the crystal violet assay; n ¼ 4 experiments. OD, Optical density.
Fig 5.
Valve smooth muscle cell (SMC) proliferation is stimulated differentially by platelet-derived growth factor (PDGF) subunit BB (PDGF-BB). Proliferation of valve vs nonvalve SMCs in response to PDGF-BB þ 2% serum (A), 1% to 10% serum (B), or a commercial SMC growth medium (C). FBS, Fetal bovine serum. Results are presented as the mean ratio (6standard error of the mean) of day 4 to day 1 cell counts or as fold of control. *P < .05 valve vs nonvalve; n ¼ 5, 6, or 9 pairs of cells for A, B, and C, respectively. the established receptors for PDGF-BB are PDGFRb and PDGFRa. To confirm this observation, we tested them using a different migration assay. In the scratch assay, the effect of PDGF-BB was completely blocked by the PDGFRb antibody in both valve and nonvalve SMCs ( Supplementary Fig 4, online only) . In addition, the antibody to FGF2 still completely blocked migration of valve SMCs but had no effect on nonvalve SMCs, thus To summarize, these data indicate that both FGF2 and PDGFRb are required for the full PDGF-BB-mediated migratory response of cultured valve SMCs, whereas FGF2 is not required by nonvalve SMCs.
FGF2 blockade does not alter SMC migration from tissue explants. To see if these growth factor mechanisms found in cell culture also functioned in the more complex tissue explants, we tested the effect of blockade of FGF2 on the migration of SMCs from valve intimalmedial explants. PDGF and FGF2 are known to mediate SMC migration in vivo. 20 Freshly dissected tissue (with endothelium and valve leaflets removed) was compared with tissue cultured for 2 days. This time frame was chosen because cells begin to migrate from tissue at day 3 (Fig 1) . We found 31 genes that were differentially expressed in valve compared with nonvalve tissue, and 6 genes were differentially expressed in the interaction between tissue type and time (Table; Supplementary Table I (Supplementary Table III , online only). Protein-protein interaction analysis (STRING database) of the differentially expressed genes indicated that a higher number of interactions (seven) exist among these genes than would be expected by chance (P ¼ .03; Supplementary  Fig 5, online only) .
Valve-specific inhibitory effect of SEMA3A on SMC migration from tissue explants. We chose SEMA3A to test (Table; Supplementary Table IV, online only) because it has been shown, along with its receptor NRP1, to be required for lymphatic valve development and to alter cell migration. Also, it is a soluble factor with characterized inhibitory reagents. [22] [23] [24] We used a peptide that competes with the immunoglobulin domain of SEMA3A for binding to NRP1 (SEMApeptide) and a peptide that competes with the MAM domain of NRP1 that mediates NRP1 dimerization (MAMpeptide; Fig 8, A) . Both of these peptides block the neural growth cone collapse activity of SEMA3A. 25 Blockade of SEMA3A with the SEMA3A
peptide increased the number of cells per explant (measures the combination of migration and postmigration proliferation) in valve but not in nonvalve explants (Fig 8, B , left and right panels, respectively). In contrast, the MAMpeptide decreased the number of cells per explant in valve and in nonvalve explants. There was no significant effect of either peptide on the number of migration-positive explants (Fig 8, C) , although the trends were the same. These data demonstrate a valve-specific stimulatory effect for the SEMA3A peptide, which indicates that SEMA3A is a valve-specific SMC migration inhibitor. There was an inhibitory effect of the MAMpeptide, which indicates that NRP1 stimulates SMC migration in both valve and nonvalve tissue. Thus, these data demonstrate a novel inhibitory role for SEMA3A in human venous valves but do not provide an explanation for the increased response to injury of the valve SMCs.
DISCUSSION
This study presents the novel observation that SMCs but not adventitial cells from the valve sinus region of human saphenous veins demonstrate more vigorous proliferation and migration in response to the injury of tissue disruption or when stimulated by PDGF or serum in culture than those from areas adjacent to the valve sinus. The explant response to injury closely parallels the time courses of cell proliferation and migration seen after vascular injury in vivo. Baboon, rat, and mouse arteries injured in vivo and baboon arterial medial explants ex vivo show entry into the cell cycle at 2 or 3 days and migration at 3 or 4 days after injury. 14, 26, 27 In comparison, the lag times for entry into the cell cycle of human saphenous vein explant SMCs and for SMC migration from tissue were 2 days and 3 or 4 days, respectively.
Mechanisms and growth factors. The augmented migration and proliferation of cultured valve SMCs compared with nonvalve SMCs in response to PDGF-BB is mediated by FGF2. Exogenous FGF stimulated and an FGF2 blocking antibody inhibited migration and proliferation of valve SMCs but not of nonvalve SMCs. Our data also suggest that the actions of PDGF-BB on valve SMCs require pathways outside of the classic PDGF receptors, PDGFRa and PDGFRb. We were unable to completely inhibit PDGF-BB-mediated migration of valve SMCs in the microchemotaxis chamber assay using maximal doses of the PDGFR blocking antibodies, whereas blockade of PDGFRb completely blocked migration of valve SMCs in the scratch assay. In contrast, blockade of PDGFRb completely blocked migration of nonvalve SMCs in both assays. However, concomitant blockade of PDGFRb and FGF2 completely blocked valve SMC migration in the chemotaxis assay ( Supplementary  Fig 3, C, online only) . This suggests the possibility of a PDGF receptor beyond PDGFRa and PDGFRb in the valve SMCs or another pathway that is operative only in the chemotaxis assay. In this regard, Pellet-Many et al 28 found an inhibitory effect of the cytoplasmic deletion mutant of NRP1 on PDGF-mediated SMC migration in the Transwell system (Fisher Scientific, Waltham, Mass) but not in the scratch assay. The Transwell system, unlike the scratch assay, develops a chemotactic gradient. Banerjee et al 29 reported that PDGF-BB binds to NRP1
and suggested that this may mediate effects of PDGF-BB on SMC migration. FGF2 has also been shown to bind to NRP1, which potentiates the growth-promoting activity of FGF2. 30 Thus, it is possible that in valve SMCs, NRP1 may mediate additional effects of both PDGF and FGF2 in a manner not involving PDGFRb, which could explain the increased effect of PDGF-BB and the valve-specific effect of FGF2 in valve SMCs. Further experiments are needed to test this hypothesis. In summary, the increased migration of cultured valve SMCs is mediated by a differential response to FGF2 by unknown mechanisms. In contrast, the increased migration of valve SMCs from tissue explants does not involve FGF2 but may be mediated by novel pathways involving some of the genes that are differentially expressed in valve tissue as highlighted by this study.
Valve wall gene expression. Consistent with differential expression, we found that the peptide with the SEMA3A sequence (SEMApeptide) had a valve-specific effect on SMC migration. However, it had a stimulatory effect. This suggests that SEMA3A is an inhibitor and so does not explain the increased migration of valve SMCs. Of interest in this regard, Movassagh et al 31 recently reported that SEMA3A inhibits the PDGF-mediated proliferation of cultured human airway SMCs, whereas Kutschera et al 32 reported no effect of SEMA3A on human umbilical artery SMC migration. Other attractive candidates for valve stimulatory genes are the tyrosine kinase receptor KIT (stem cell factor receptor), GATA3, and N-cadherin (CDH2). KIT plays a positive role in vasculogenesis and injury-mediated intimal hyperplasia 33, 34 and is more highly expressed in valve tissue. GATA3 is required for tissue regeneration, 35 mediates SMC hyperplasia in lung injury models, 36 and is more highly expressed in valve tissue. Finally, Clinical implications. The observation of a greater response to injury by the valve wall segment has implications for vein graft failure, chronic venous insufficiency, and deep venous thrombosis, each of which represents a different injury to the venous wall (ie, arterial pulse pressure and flow, venous hypertension, and the local thromboinflammatory effects of a thrombus, respectively). Regarding arterial vein graft failure, 8% to 18% of lesions occur at valve sites. [4] [5] [6] [7] In the case of reversed vein grafts, most of the valve leaflets become fibrotic, which may result from the greater migratory and proliferative phenotype of the valve SMC. Regarding venous thrombosis, the valve sinus is often the site of thrombus initiation and has been reported to express less fibrinolytic activity. 43 Activated platelets in the thrombus release the contents of their granules, which include PDGF. Our data indicate that SMCs in the valve sinus have a greater migratory and proliferative response to PDGF than do the nonvalve SMCs, which could lead to greater wall thickening in the valve area. In turn, this thickening of the vein, by vessel remodeling or luminal encroachment, may then lead to valve dysfunction, as has been suggested for the valve and wall thickening observed with increasing age. 1, 44, 45 Increased valve SMC activation, particularly the immune and inflammatory pathways indicated by our GO results (Supplementary Tables II and III , online only), may also contribute to the thrombotic response. A link between venous thrombosis, sterile inflammation, and the innate immune response has been suggested as TLR9 knockout mice had larger venous thrombi than wild-type mice. 46 A further link between immune function and venous injury is that long-term vein bypass graft failure has been associated with single-nucleotide polymorphisms in complement component (3b/4b) receptor 1, MICA, and HLA-DPB1, the last two of which are human leukocyte antigen class I and class II major histocompatibility complex components, respectively. 47 Finally, the SMCs of experimental vein grafts show inflammatory activation. 48 This study is significant in that the GO results demonstrate that the valve wall further increases the activities of these immune/inflammation pathways. Whether this plays a role in post-thrombotic syndrome, which occurs in w30% of patients with deep venous thrombosis, 3 or chronic venous insufficiency is not clear and could not be studied in the current work because of the difficulty of obtaining histologic specimens. This limitation in our methodology cannot be replaced by animal models as they lack venous valves. 49 
CONCLUSIONS
SMCs of the valve sinus exhibit an exaggerated response to injury compared with SMCs of the nonvalve wall, which may explain the propensity of the valve wall to fail in arterial bypass grafts and for the valves to fail after thrombotic events. 
APPENDIX (online only).
Supplementary Methods (online only) Veins, tissue culture, and cell culture. Human saphenous vein remnants were obtained from patients undergoing coronary artery bypass or peripheral vascular bypass operations under protocols approved by the Institutional Review Boards of the University of Washington and the Benaroya Research Institute. All subjects gave informed consent. Vein sections that were marked intraoperatively with blue dye were discarded. Veins were dissected free of loose, extraneous tissue, and the veins were opened longitudinally. Endothelium was removed by gently wiping with a cotton-tipped swab. Then, segments that comprised the valve sinus or were remote from the valve sinus were selected. The valve leaflets were removed. For both types of segments, the intimalmedial layer containing smooth muscle cells (SMCs) was dissected free from the adventitia. To confirm the anatomic accuracy of the dissection of the vein wall into separate components of adventitia and intima-media, immunostaining for smooth muscle a-actin was performed on partially dissected specimens. An example is seen in Supplementary Fig 1, A and B (online only) . The dissection plane goes through the outer media, leaving an intimal-medial preparation without adventitia ( Supplementary Fig 1, B, online only) .
Using a customized McIlwain tissue chopper, 2.5 mm 2 explants of the intimal-medial and adventitial layers were made. Explants (15 replicates/flask for each tissue type for each vein) were maintained in 1 mL of 20% fetal bovine serum/Dulbecco modified Eagle medium (DMEM). Migration of cells from tissue explants was assessed daily, as follows: (1) an explant was called migration positive if at least one attached, spread cell was observed outside the explant; and (2) the number of migrated cells (up to 100) was counted for each explant. The first method measures only migration, whereas the second method measures the combination of migration and postmigration proliferation. and made by GenScript [Piscataway, NJ]) were added with the growth medium, which was changed every 2 days. When cells surrounding the explants became confluent (2-3 weeks), the medium was changed to Smooth Muscle Cell Growth Medium (Cell Applications, Inc, San Diego, Calif), which contains 5% fetal bovine serum and undisclosed amounts of epidermal growth factor, FGF2, insulin, and heparin (James Yu, Cell Applications, personal communication). This medium was also used for subsequent growth of passaged cells on collagencoated plasticware (10 mg/mL bovine skin collagen in phosphate-buffered saline [PBS] overnight at 4 C).
Tissue histology and immunostaining. A different method of tissue culture was used to compare SMC proliferation and death in valve vs nonvalve tissue. After veins were cleaned of extraneous tissue and opened longitudinally, 2-cm-long specimens with contiguous valve and nonvalve areas were cut into 2-mm-wide, full-thickness (ie, with adventitia and intima-media) longitudinal specimens using the tissue chopper. These valve and nonvalve specimens were then cultured up to 4 days in 20% fetal bovine serum/DMEM. Tissue was fixed in 10% formalin at 4 C overnight and then stored in 70% ethanol until processed for embedding in paraffin. Terminal deoxynucleotidyl transferase dUTP nick end labeling staining was performed using a kit with Methyl Green counterstaining (In Situ Cell Death Detection Kit; Roche, Inc, Branchburg, NJ). For a proliferation index, immunostaining Ki67 was performed (0.5 mg/mL SP6; Abcam, Inc, Cambridge, Mass). Cell migration, growth, and attachment. Cell migration in microchemotaxis chambers (Neuro Probe, Inc, Gaithersburg, Md) was performed as previously described. 8 For the scratch migration, assay cells were seeded at 2 Â 10 5 /well in 12-well plates. Once confluent, pressure on half of a straight-edge razor (held steady by a custom apparatus) was used to make a line in the plastic dish while cells were removed on one side with a cotton swab. The plate was turned 180 degrees, and the process was repeated so that a strip of cells 2 to 3 mm wide remained along the diameter of the dish. After washing cells with PBS and bovine basal SMC medium, cells were preincubated in bovine basal medium 6 anti-PDGF receptors a and b (5 mg/mL each), anti-FGF (30 mg/mL), or immunoglobulin G. After 2 hours, 10 ng/mL of PDGF subunit BB (PDGF-BB) was added to the wells other than control wells. The cells that crossed the scratch line were counted after 48 hours. The 3-day cell growth assay was performed by seeding 48,000 cells in 5% fetal bovine serum in bovine basal SMC medium (Cell Applications, Inc) in triplicate wells of six-well plates. The next day, triplicate wells were counted to determine plating efficiency, and the medium was changed in the remaining wells to 2% fetal bovine serum 6 10 ng/mL PDGF-BB. Preliminary experiments were performed to determine that 2% is the optimal level of serum to maintain a constant cell number. Final cell counts were performed at day 4.
For the attachment assay, 3 Â 10 5 cells were washed once with 1 mmol/L ethylenediaminetetraacetic acid in PBS and twice with soybean trypsin inhibitor (0.5 mg/ mL in PBS), then resuspended in bovine basal SMC medium containing 1 mg/mL bovine serum albumin.
Cells were then seeded into precoated (10 mg/mL bovine type I collagen in PBS, 1 hour at 37 C) 96-well plates.
Uncoated wells were used as negative control. After incubation for 1 hour, the wells were washed three times, and remaining cells on the well were stained for 15 minutes with 0.2% crystal violet in 20% methanol. The dye was solubilized by adding 0.1 mol/L sodium citrate in 50% ethanol (pH 4.2) and quantified by measuring absorbance at 550 nm. FGF2 enzyme-linked immunosorbent assay and Western blot. Cells were seeded at 2 Â 10 5 /well in sixwell plates in Cell Applications SMC growth medium. The next day, the cell layer was washed and incubated for 30 minutes with serum-free bovine basal SMC medium. The medium, a heparin-releasable fraction, and the cell layer for a control group were then harvested as described previously. 9 Fresh serum-free medium was then added with 10 ng/mL PDGF-BB, and fractions were harvested at 0.5 hour, 1 hour, and 4 hours. Heparinreleasable fractions and medium were concentrated w10-fold using Microcon-10 Ultra centrifugal filters (EMD Millipore, Billerica, Mass). Levels of FGF2 were measured using a commercial sandwich enzyme-linked immunosorbent assay for human FGF2 (DY233; R&D Systems, Minneapolis, MN). For Western blotting, cellular proteins were extracted in HEPES extraction buffer (25 mM HEPES, pH 7.5; 5 mM ethylenediaminetetraacetic acid; 5 mM egtazic acid; 150 mM sodium chloride; 100 mM sodium pyrophosphate tetrabasic; 50 mM sodium fluoride; 1 mM benzamidine; 1% Triton X-100; 10% glycerol; 0.1% b-mercaptoethanol; 1 mg/mL pepstatin A; 5 mg/mL leupeptin; and 5 mg/mL aprotinin). The same amount of protein was size fractionated on a 10% sodium dodecyl sulfate-polyacrylamide gel, transferred to a polyvinylidene difluoride membrane (Bio-Rad, Richmond, Calif), and probed with 1 mg/mL rabbit anti-human FGF2 (sc-79; Santa Cruz Biotechnology, Santa Cruz, Calif) overnight, followed by peroxidase-conjugated anti-rabbit antibody (KPL, Gaithersburg, Md). Chemiluminescent signal development was performed using LumiGLO Reserve Chemiluminescent substrate (KPL) according to the manufacturer's protocol. Relative protein quantification was performed by scanning autoradiographs and analyzed by Image J software (National Institutes of Health, Bethesda, Md).
Immunofluorescent analysis. Subconfluent cells grown in SMC growth medium (Cell Applications, Inc) on glass coverslips were fixed in 4% paraformaldehyde for 10 minutes. The samples were permeabilized with 0.1% Triton X-100 in PBS for 2 minutes on ice. After blocking in 5% skim milk, the samples were stained with primary antibodies, including polyclonal rabbit antihuman smooth muscle myosin heavy chain (Abcam plc, Cambridge, UK) and monoclonal rabbit anti-human smooth muscle a-actin (Abcam) for 1 hour at room temperature. Corresponding secondary antibody was labeled with Alexa Fluor 555 (ThermoFisher Scientific, Waltham, Mass) for 1 hour at room temperature. The samples were mounted using the ProLong Gold Antifade Reagent with DAPI (ThermoFisher Scientific). Staining intensity was quantified using the image analysis software Image J. RNA purification, RNA sequencing, and pathway enrichment analysis. Dissected intima-media specimens from valve and nonvalve areas (w1 cm 2 /condition) were immediately placed in RNAlater (ThermoFisher Scientific) at 4 C overnight and then frozen at À80 C until processed. Other samples was maintained in 20% fetal bovine serum/DMEM for 2 days before placement in RNAlater. RNA was purified using TRIzol extraction coupled with Quick-RNA MiniPrep columns as instructed with DNase I treatment (Zymo Research, Irvine, Calif). The OD260/OD280 was 2.05 6 0.02 (mean 6 standard error of the mean, n ¼ 40). Sequencing libraries were constructed from total RNA using TruSeq RNA Sample Preparation Kits v2 (Illumina, San Diego, Calif) and clustered onto a flow cell, using a cBOT amplification system with a HiSeq SR v3 Cluster Kit (Illumina). Single-read sequencing was carried out on a HiSeq2500 sequencer (Illumina), using a HiSeq SBS v3 Kit to generate 50-base reads, with a target of approximately 10 million reads per sample. FASTQs were aligned to the human reference genome to generate gene counts. The RNA sequencing data were filtered for genes that had at least one raw count in 10% of the libraries and then normalized. The normalized data were analyzed for differentially expressed genes while blocking by donor, using voom in the limma R package. 10 The R package goseq was used to find Gene Ontology terms that were over-represented or under-represented by the differentially expressed genes in the valve and day comparisons.
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Statistical analysis. Repeated-measures analysis of variance (Figs 1, 2, 5 , B and C, 7, and 8) was performed using SPSS (version 19; IBM Corp, Armonk, NY). Paired two-way analysis of variance ( Supplementary Fig 2, A) and the Wilcoxon signed rank test (Figs 3, 4 , 5, A, and 6; Supplementary Figs 2, B-D, and 4) were performed using Prism 6 (GraphPad Software, Inc, La Jolla, Calif). Data are presented as the mean 6 standard error of the mean. Supplementary Fig 2 (online only) . Valve (VSMC) and nonvalve (NVSMC) smooth muscle cells (SMCs) express equivalent levels of fibroblast growth factor, but only valve SMCs migrate in response to fibroblast growth factor 2 (FGF2). A, Levels of FGF2 in the heparin-releasable fraction, medium, and cell layer (left to right, respectively) determined by enzyme-linked immunosorbent assay before and after treatment of valve and nonvalve SMCs with 10 ng/mL platelet-derived growth factor subunit BB (PDGF-BB) for up to 4 hours; n ¼ 7 different pairs of valve and nonvalve SMCs for each time point. B, A representative Western blot of FGF2 in the total cell layer extract of valve and nonvalve SMCs is presented in the left panel, and quantification of the 18-kD, 22-kD, and 24-kD isoforms of FGF2 in five different pairs of valve and nonvalve SMCs is presented in the right panel. Supplementary Fig 1 (online only) . Dissection of venous tissues. A, Representative photograph of a dissected valve sinus wall intima-media without removal of the valve leaflets (arrows indicate the intact valve leaflets) and the adventitia (with a dot of blue marking dye). B, Photomicrograph of a vein explant immunostained for smooth muscle a-actin. The dashed line marks the medial-adventitial border. The dissection plane through the outer media leaving variable amounts of media with the adventitial layer is indicated by the arrow. The arrowhead shows a valve leaflet. 
Supplementary
